摘要
目的探讨分析依替米星联合美罗培南与哌拉西林/他唑巴坦对多药耐药铜绿假单胞菌肺部感染的治疗,为临床提供一定指导意义。方法选择2013年2月-2015年2月医院住院治疗96例多药耐药铜绿假单胞菌肺部感染患者,按照随机数字表法将其分为观察组和对照组,每组各48例,对照组患者给予依替米星治疗,观察组患者给予依替米星联合美罗培南与哌拉西林/他唑巴坦治疗,对两组患者预后进行对比分析。结果观察组患者治疗有效率91.67%,显著高于对照组41.67%,观察组患者病死率2.08%,低于对照组18.75%,差异均有统计学意义(P<0.05);观察组患者住院时间为(20.14±11.37)d,显著短于对照组(55.22±23.54)d,差异有统计学意义(P<0.05);观察组患者啰音消失、咳嗽咳痰消失时间、体温恢复及白细胞恢复时间均显著短于对照组,差异有统计学意义(P<0.05)。结论依替米星联合美罗培南与哌拉西林/他唑巴坦对多药耐药铜绿假单胞菌肺部感染治疗效果显著,并且预后效果良好,能明显缩短症状改善时间,从而缩短患者住院时间。
OBJECTIVE To explore the prognosis of etimicin combined with meropenem,piperacillin/tazobactam for multi-drug resistant Pseudomonas aeruginosalung infection,so as to provide a certain guiding significance for clinic.METHODS A total of 192 patients with P.aeruginosalung infection in our hospital from Feb.2013 to Feb.2015 were chosen.According to the random number table,they were divided into observation group and control group,48 cases in each group.Etimicin was provided to the control group patients,etimicin combined with meropenem and piperacillin/tazobactam for observation group patients.The prognosis were compared in the two groups.RESULTS Effective rate in observation group was 91.67%,significantly higher than 41.67%in the control group,and mortality rate in observation group was 2.08%,significantly lower than the 18.75%in the control group（P〈0.05）.Hospitalization time in observation group was（20.14±11.37）d,significantly shorter than the control group（55.22±23.54）d（P〈0.05）.Rales and cough disappeared time,temperature and leukocytes recovery time in observation group were significantly shorter than those in control group（P〈0.05）.CONCLUSION The treatment of etimicin combined with meropenem and piperacillin/tazobactam for multi-drug resistant P.aeruginosalung infection is significant,and the prognosis is good,which can significantly shorten the time of symptoms,so as to reduce hospitalization time.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2016年第19期4339-4341,共3页
Chinese Journal of Nosocomiology
基金
浙江省卫生厅医药卫生计划基金资助项目(2013KYA080)
